OMass Therapeutics
OMass Therapeutics is a UK-based biotech company that uses mass spectrometry to discover new drugs, particularly for membrane receptors and other complex targets. The company has raised $162M, including a Series B in May 2023, and employs 76 people.
The growth story
OMass Therapeutics grew from 60 to 76 employees between 2022 and 2026, raising $162M along the way, most recently a Series B in May 2023.
About
OMass Therapeutics develops drug discovery tools based on high-resolution mass spectrometry, which allows them to study intact protein assemblies and identify drug candidates that modulate complex formation. Their focus is on membrane receptors and other complex targets for severe unmet medical needs.
The company has raised $162M from notable investors including Syncona, GV, and Sanofi Ventures, with its latest Series B closing in May 2023. With 76 employees, OMass operates primarily in research, leveraging its proprietary technologies to advance drug discovery.
Founders and leadership
OMass Therapeutics is led by a research-focused team, with 26 employees dedicated to research functions. The company is headquartered in Oxford, England, and maintains a relatively flat organizational structure with a median tenure of 2 years.
The OMass Therapeutics org chart
Ros Deegan (CEO) leads 20 mapped leaders with 4 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 32 (-20% YoY), Business Development 14 (0% YoY), Administrative 5 (-17% YoY), Engineering 3 (0% YoY), Operations 3 (-25% YoY), Education 3 (0% YoY).
Talent flow
OMass recruits heavily from GSK, the University of Nottingham, and the University of Oxford, with 9, 7, and 4 hires respectively. Alumni often move to academic institutions like the University of Oxford or biotech firms such as Nxera Pharma and Amphista Therapeutics.
Most common previous employers of OMass Therapeutics staff: GSK (9), University of Nottingham (7), University of Oxford (4), AstraZeneca (3), Excellerate Bioscience (3), Evotec (3). Former OMass Therapeutics employees most often moved to University of Oxford (4), Nxera Pharma (3), Ellison Institute of Technology Oxford (2), University of Nottingham (2), Amphista Therapeutics (1), SV Health Investors (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at OMass Therapeutics: Molecular Biology (24), Drug Discovery (22), Life Sciences (22), Biochemistry (20), Research Skills (18), Pharmaceutics (18), Biotechnology (17), Drug Development (16).
Where the team actually sits
OMass Therapeutics people are concentrated in England, United Kingdom (31), United Kingdom (12), Greater Oxford Area (6), Greater Nottingham (2).
Search footprint
OMass Therapeutics attracts about 322 organic search visits a month, traffic worth roughly $0K a month if bought through ads. It gained 3 ranking keywords and lost 13 in the last period.
What employees say
- Compensation
- 3.80 / 5
- Career opportunities
- 3.40 / 5
- Senior management
- 4.10 / 5
- Work-life balance
- 4.60 / 5
Frequently asked
OMass Therapeutics has 76 employees as of September 2026.
OMass Therapeutics has raised $162M in total, most recently a Series B round in May 2023.
OMass Therapeutics was founded in 2016 by Jonathan Hopper.
Ros Deegan (CEO) sits at the top of OMass Therapeutics's reporting structure, with 4 direct reports.
The most common previous employers of current OMass Therapeutics staff are GSK (9 people), University of Nottingham (7 people), University of Oxford (4 people).
Former OMass Therapeutics employees most often move to University of Oxford (4), Nxera Pharma (3), Ellison Institute of Technology Oxford (2).
OMass Therapeutics attracts about 322 organic search visits a month, worth roughly $0K a month in equivalent ad spend.
The most common skills among OMass Therapeutics staff are Molecular Biology, Drug Discovery, Life Sciences, Biochemistry, Research Skills.
OMass Therapeutics staff are concentrated in England, United Kingdom (31), United Kingdom (12), Greater Oxford Area (6).
OMass Therapeutics has about 32 people in Research, down 20% over the past year, as of September 2026.
OMass Therapeutics has about 14 people in Business Development, up 0% over the past year, as of September 2026.
Computed from 55 current and 58 former OMass Therapeutics profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.